Within the last few days, there has been breaking news regarding the war on gonorrhea. Nuzolvence (zoliflodacin) was FDA approved on December 13, 2025, and Blujepa (gepotidacin) was FDA approved on December 11, 2025.These new oral treatments are particularly important given the global rise in gonococcal drug resistance and the convenience they offer over injectable options, potentially improving patient adherence and public health outcomes. Listen in for details.

1. ​ FDA News Release. FDA Approves Two Oral Therapies to Treat Gonorrhea. fda.gov
2. ​ Innoviva Specialty Therapeutics. U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-Dose Oral Antibiotic, for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents. innovivaspecialtytherapeutics.com
3. ​ CNN. New gonorrhea treatments approved by FDA for first time in decades.
4. ​ The New York Times. F.D.A. Approves Two New Drugs to Treat Gonorrhea.
5. ​ STAT. FDA approves zoliflodacin, a gonorrhea pill marketed as Nuzolvence.
6. ​ Fierce Pharma. FDA endorses another gonorrhea treatment, blessing Innoviva’s Nuzolvence.

https://strongcoffeecompany.com/discount/CHAPANOSPINOBG